ESTRO 2025 - Abstract Book

S1851

Clinical – Upper GI

ESTRO 2025

3951

Mini-Oral Predicting Survival in Pancreatic Cancer: Insights from Systemic Inflammatory Scores

Ece Ercan, Melisa Bagci Kilic, Medine Ilay Anli, Hilal Alkis Radiation Oncology, Marmara University, Istanbul, Turkey

Purpose/Objective: Systemic inflammatory markers have demonstrated prognostic value in patients with pancreatic cancer. In this study, we aimed to determine the relationship between survival and Gustave Roussy Immune (GRIm) Score, Lung Immune Prognostic Index (LIPI), and The Scottish Inflammatory Prognostic Score (SIPS) in patients with pancreatic adenocarcinoma (PAC) who received radiotherapy (RT). Material/Methods: A total of 74 patients treated with RT were included in this study. Female/Male ratio was 26/48. Median age was 62 (39-78) years. Patients with metastatic disease at the time of diagnosis were excluded from the study. The goal of RT was adjuvant in 55 (74.3%) patients, definitive in 14 (18.9%), palliation in 4 (5.4%), and neoadjuvant in 1 (1.4%). Median RT dose was 50.4 Gy (30 - 56 Gy). Absolute values of white blood cell count (WBC), neutrophil (N), monocyte (M), lymphocyte (L), platelets (P), hemoglobin (H), albumin (ALB), and lactate dehydrogenase (LDH) obtained from routine blood tests at the time of diagnosis were recorded. Thereafter, GRIm, SIPS, and LIPI scores were determined. GRIm scores were categorized as low or high based on ALB, LDH, and N/L ratio. SIPS was classified into three groups based on ALB and N: low risk (0), moderate risk (1), and high risk (2). LIPI was determined according to dNLR [N/(WBC−N)] and LDH levels and classified as good, intermediate, and poor. Kaplan Meier analysis was used to determine overall survival (OS). Results: Median follow-up time was 23.6 months (3-117). GRIm score, SIPS, and LIPI were significantly associated with OS (p<0.05) (Figure). Patients with low GRIm score (p=0.015) and low risk SIPS (p = 0.048) had better OS. Patients with good LIPI score were found to have better OS (p= 0.037).

Figure: Survival analysis based on pre-treatment scores: (A) GRIm, (B) SIPS, and (C) LIPI.

Conclusion: GRIm, SIPS, and LIPI scores at the time of diagnosis in non-metastatic PAC may be useful for predicting survival.

Keywords: Pancreatic cancer, Inflammatory scores, Survival